Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPau AbrisquetaJCJacob Haaber ChristensenAFAlexander Fosså

Discussion

Loading...

Member takes

Overview

Combination therapy with epcoritamab and rituximab demonstrates 88% complete response in patients with follicular lymphoma, suggesting enhanced long-term management.

Key Points

  • Deep, durable remissions were recorded, achieving an 88% complete response rate over a 3-year follow-up.
  • Patients showed a 33-month estimated duration of complete response and promising progression-free survival rates.
  • The phase 1b/2 trial evaluated treatment effectiveness through rigorous monitoring of safety and efficacy parameters.
  • Results suggest the safety profile of epcoritamab allows for effective management in patients with follicular lymphoma.

Cite This Study

Abrisqueta et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4bfhttps://doi.org/10.1182/blood-2025-465
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  2. 2Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025
  3. 3Fixed-duration epcoritamab in combination with bendamustine + Rituximab (BR) for first-line (1L) treatment of follicular lymphoma (FL): 3-year results from EPCORE NHL-2 arm 3 demonstrate deep and durable responses with manageable safety2025
  4. 4Sustained remissions beyond 4 years with epcoritamab monotherapy: Long term follow-up results from the pivotal EPCORE NHL-1 trial in patients with relapsed or refractory large B-cell lymphoma2025
  5. 5Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025